Tenor Capital Management adds BioPharmX Corp (BPMX) to its portfolio

BioPharmX Corp (BPMX) : Tenor Capital Management added new position in BioPharmX Corp during the most recent quarter end. The investment management firm now holds 63,000 shares of BioPharmX Corp which is valued at $37,800 , the company said in a statement filed on May 13, 2016 with the SEC.BioPharmX Corp makes up approximately 1.48% of Tenor Capital Management’s portfolio.

Other Hedge Funds, Including , Nexthera Capital Lp added BPMX to its portfolio by purchasing 345,440 company shares during the most recent quarter which is valued at $207,264. BioPharmX Corp makes up approx 0.23% of Nexthera Capital Lp’s portfolio.Rtw Investments boosted its stake in BPMX in the latest quarter, The investment management firm added 330,000 additional shares and now holds a total of 700,636 shares of BioPharmX Corp which is valued at $420,382. BioPharmX Corp makes up approx 0.17% of Rtw Investments’s portfolio.Blackrock Fund Advisors boosted its stake in BPMX in the latest quarter, The investment management firm added 308 additional shares and now holds a total of 1,774 shares of BioPharmX Corp which is valued at $1,064.

BioPharmX Corp opened for trading at $0.599 and hit $0.66 on the upside on Wednesday, eventually ending the session at $0.63, with a gain of 5.18% or 0.031 points. The heightened volatility saw the trading volume jump to 16,297 shares. Company has a market cap of $18 M.

Many Wall Street Analysts have commented on BioPharmX Corp. Maxim Group Initiated BioPharmX Corp on Apr 15, 2016 to “Buy”, Price Target of the shares are set at $3.H.C. Wainwright Initiated BioPharmX Corp on Apr 7, 2016 to “Buy”, Price Target of the shares are set at $3.

BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter or OTC products that address markets in women’s health and dermatology. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01 a topical antibiotic for the treatment of acne and BPX03 a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition or FBC and cyclic mastalgia. The Company’s commercial product VI2OLET iodine is an OTC dietary supplement molecular iodine tablet that promotes breast health and is for the alleviation of benign breast pain associated with fibrocystic breast condition or FBC. The Company has one wholly owned subsidiary BioPharmX Inc.

Leave a Reply

BioPharmX Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioPharmX Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.